Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

被引：7

作者：

Otten, Marieke H. ^{[1
]}

Prince, Femke H. M. ^{[1
]}

Twilt, Marinka ^{[2
]}

van Rossum, Marion A. J. ^{[3
]}

Armbrust, Wineke ^{[4
]}

Hoppenreijs, Esther P. A. H. ^{[5
]}

Kamphuis, Sylvia ^{[1
]}

Koopman-Keemink, Yvonne ^{[6
]}

Wulffraat, Nico M. ^{[7
]}

Gorter, Simone L. ^{[8
]}

ten Cate, Rebecca ^{[2
]}

van Suijlekom-Smit, Lisette W. A. ^{[1
]}

机构：

[1] Erasmus MC, Sophia Childrens Hosp, Dept Paediat, NL-3000 CB Rotterdam, Netherlands

[2] Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands

[3] Emma Childrens Hosp, Acad Med Ctr, Jan van Breemen Inst, Dept Paediat, Amsterdam, Netherlands

[4] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, NL-9713 AV Groningen, Netherlands

[5] Radboud Univ Nijmegen, Med Ctr, Dept Paediat, NL-6525 ED Nijmegen, Netherlands

[6] Hagaziekenhuis Juliana Childrens Hosp, Dept Paediat, The Hague, Netherlands

[7] Utrecht MC Wilhelmina Childrens Hosp, Dept Paediat, Utrecht, Netherlands

[8] Univ Limburg, Acad Hosp Maastricht, Dept Internal Med, Rheumatol Subdiv, Maastricht, Netherlands

来源：

JOURNAL OF RHEUMATOLOGY | 2010年 / 37卷 / 03期

关键词：

JUVENILE IDIOPATHIC ARTHRITIS; ANTIRHEUMATIC AGENTS; TUMOR NECROSIS FACTOR-alpha; DRUG ADMINISTRATION SCHEDULE; TREATMENT OUTCOME; ARTHRITIS; RHEUMATOID-ARTHRITIS; EFFICACY; CHILDREN; THERAPY; SAFETY;

D O I：

10.3899/jrheum.090550

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

引用

页码：665 / 667

页数：3

共 14 条

[1]

[Anonymous], 2002, ARTHRITIS RHEUM, V46, P328

[2] Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 [J].

Furst, D. E. ;

Breedveld, F. C. ;

Kalden, J. R. ;

Smolen, J. S. ;

Burmester, G. R. ;

Sieper, J. ;

Emery, P. ;

Keystone, E. C. ;

Schiff, M. H. ;

Mease, P. ;

van Riel, P. L. C. M. ;

Fleischmann, R. ;

Weisman, M. H. ;

Weinblatt, M. E. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 :2-22

[3]

Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202

[4] The German etanercept registry for treatment of juvenile idiopathic arthritis [J].

Horneff, G ;

Schmeling, H ;

Biedermann, T ;

Foeldvari, I ;

Ganser, G ;

Girschick, HJ ;

Hospach, T ;

Huppertz, HI ;

Keitzer, R ;

Küster, RM ;

Michels, H ;

Moebius, D ;

Rogalski, B ;

Thon, A .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1638-1644

[5] Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate [J].

Kavanaugh, A. ;

Klareskog, L. ;

van der Heijde, D. ;

Li, J. ;

Freundlich, B. ;

Hooper, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (10) :1444-1447

[6] Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies [J].

Kievit, W. ;

Fransen, J. ;

Adang, E. M. ;

Kuper, H. H. ;

Jansen, T. L. ;

De Gendt, C. M. A. ;

De Rooij, D. J. R. A. M. ;

Brus, H. L. M. ;

De Laar, M. A. F. J. van ;

Van riel, P. C. L. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :844-849

[7] Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis [J].

Lovell, Daniel J. ;

Reiff, Andreas ;

Ilowite, Norman T. ;

Wallace, Carol A. ;

Chon, Yun ;

Lin, Shao-Lee ;

Baumgartner, Scott W. ;

Giannini, Edward H. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1496-1504

[8] Etanercept in children with polyarticular juvenile rheumatoid arthritis. [J].

Lovell, DJ ;

Giannini, EH ;

Reiff, A ;

Cawkwell, GD ;

Silverman, ED ;

Nocton, JJ ;

Stein, LD ;

Gedalia, A ;

Ilowite, NT ;

Wallace, CA ;

Whitmore, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (11) :763-769

[9] Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis - Interim results from an ongoing multicenter, open-label, extended-treatment trial [J].

Lovell, DJ ;

Giannini, EH ;

Reiff, A ;

Jones, OY ;

Schneider, R ;

Olson, JC ;

Stein, LD ;

Gedalia, A ;

Ilowite, NT ;

Wallace, CA ;

Lange, M ;

Finck, BK ;

Burge, DJ .

ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :218-226

[10]

*NAT I CLIN EXC, 35 NAT I CLIN EXC

← 1 2 →